Table 3.

Intolerances leading to discontinuation of first-line TKI within 1 year of initiation among patients who switched to a second-line TKI within 1 year from initiating first-line TKI. The denominator is the number of patients in the column whose primary reason for discontinuation of first-line TKI is intolerance.

	Italy					Europe
Event, N (%)	Imatinib (Retro) (N=0)	Imatinib (Pro) (N=6)	Dasatinib (N=1)	Nilotinib (N=2)	All patients (N=9)	Imatinib (Retro) (N=2)	Imatinib (Pro) (N=14)	Dasatinib (N=8)	Nilotinib (N=5)	All patients (N=29)
Arthralgia	0 (0.0)	1 (16.7)	0 (0.0)	0 (0.0)	1 (11.1)	0 (0.0)	2 (14.3)	0 (0.0)	0 (0.0)	2 (6.9)
Erythema	0 (0.0)	1 (16.7)	0 (0.0)	0 (0.0)	1 (11.1)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Generalised oedema	0 (0.0)	2 (33.3)	0 (0.0)	0 (0.0)	2 (22.2)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Neutropenia	0 (0.0)	1 (16.7)	0 (0.0)	1 (50.0)	2 (22.2)	1 (50.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (3.4)
Oedema	0 (0.0)	2 (33.3)	0 (0.0)	0 (0.0)	2 (22.2)	0 (0.0)	1 (7.1)	0 (0.0)	0 (0.0)	1 (3.4)
Platelet count decreased	0 (0.0)	0 (0.0)	1 (100.0)	0 (0.0)	1 (11.1)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Thrombocytopenia	0 (0.0)	1 (16.7)	0 (0.0)	2 (100.0)	3 (33.3)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)

Pro: prospective; Retro: retrospective; TKI: tyrosine kinase inhibitor.